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A B S T R A C T
Dietary treatment is the cornerstone of therapy for phenylketonuria (PKU), but adherence to low- phenylalanine
diet progressively decreases after adolescence. We designed a survey to characterize the dietary habits of Italian
adult PKU patients and to identify psychological factors influencing disease perception and adherence to diet.
Participants to the survey (n=111; response rate 94%) were asked to complete a structured questionnaire.
Patients appeared to have an altered perception and awareness of the disease. About 40% of them did not
consider PKU a disease and, despite declaring regular monitoring of phenylalanine levels (85%), nearly half of
them reported a high plasma value over the last 6months (> 600 μmol/L, 48%) or were unable to specify it
(31%). Adherence to PKU diet was unsatisfactory, with increased consumption of natural protein sources and
reduced daily use of amino-acid supplements (< 4–5 times/day in 82% patients). In addition to the intrinsic
characteristics of AA formula (palatability, ease of use), the most important factor influencing their consumption
was the increased social pressure associated with their use (55%). Plasma phenylalanine periodical measure-
ments (61%) and examinations at metabolic centers (49%) were considered relevant for compliance to diet. In
Italian adult PKU patients dietary management was found to be inadequate, likely due to inappropriate per-
ception and knowledge of the disease, and lack of awareness of the negative impact of poor metabolic control in
adult life. Clinicians should consider implementing more intense and tailored educational measures, as well as
structured transitional care processes.
1. Introduction
Phenylketonuria (PKU) is an autosomal recessive metabolic disorder
that affects about one person every 10,000 births in Europe [1]. PKU is
determined by the impairment of phenylalanine hydroxylase (PAH)
activity resulting in decreased phenylalanine (PHE) conversion to tyr-
osine. Deficiency of the hepatic PAH results in a broad spectrum of
hyperphenylalaninemia (HPA) ranging from very mild HPA (blood
PHE: 120–600 μmol/L), to mild PKU (blood PHE: 600–1200 μmol/L)
and classic PKU (blood PHE > 1200 μmol/L) [2]. Accordingly, the
alteration leads to high plasma concentrations of phenylalanine (and
decreased tyrosine), which accumulates in the tissues and causes da-
mage if left untreated. The most serious consequence is the impaired
development of the central nervous system, with intellectual disability
frequently being associated with other manifestations, such as motor
disturbances, psychiatric symptoms, aberrant behavior, and epilepsy
[3]. Low-PHE diet (a personalized dietary plan based on the con-
sumption of normal food sources, low-protein foods and the use PHE-
free protein substitutes to cover protein requirements) is the mainstay
of treatment of PKU [4]. During childhood adherence to diet is very
high, but progressively decreases after adolescence [5–7]. This is likely
due to increasing independency of patients from the family as well as to
psychological and social burden both in patients and their families [8,
9].
Dietary management in childhood is associated with neurocognitive
outcome [10–12]. Individuals with early-treated PKU can achieve
normal or near-normal IQ if they maintain good metabolic control
through dietary restriction until the age of 12, but even after this age
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there is a correlation between current phenylalanine levels and IQ
among individuals aged between 0 and 39 years [13]. PHE levels may
still influence the adolescent and adult brain anyway, and patients with
elevated PHE levels have been reported to show neuroradiological [14]
and neuropsychological deficits, as well as impairment of executive
function, speed and attention [15, 16]. In adult PKU patients (age >
32 years) poor cognitive performance, assessed by IQ and information
processing, was found to correlate with higher blood PHE levels in
adolescence, possibly related to early relaxation of diet at age 10 [15].
Besides, neuroimaging structural alterations in the white matter have
been reported in adult PKU patients with insufficient metabolic control,
although the lesions do not appear to be associated with clinical
symptoms [11, 16, 17]. As there is currently no strong evidence that it
is safe to discontinue dietary treatment in adults, lifelong treatment is
recommended, even though it is acknowledged that dietary manage-
ment is associated with significant patient burden [3, 18]. In recent
years, the focus has increasingly shifted to the Quality of Life (QoL) of
PKU patients previously receiving dietary intervention. Although QoL
scores of PKU patients are reported to be generally similar to healthy
controls, a chronic disease can engender anxiety and fear of not being
able to adequately control the course of the disease [19].
Reviews have recently pointed out that there is a paucity of studies
examining the influence of demographic and psychological factors on
metabolic control in adult PKU patients [8, 20]. Moreover, no studies
have addressed the issue from the point of view of the patient. The aim
of this multicenter survey (Analysis of the mosT relevanT and pre-
dIctive facTors inflUencing aDherence to PKU diEt [ATTITUDE]) was to
collect information on the subjective perceptions of the patients by
carrying out in-depth interviews of Italian adult PKU patients.
2. Materials and methods
Over a 12month period (from August 2016 to August 2017) 116
adult patients were recruited for the study. Patient inclusion criteria for
enrollment were: confirmed diagnosis of PKU by neonatal screening,
age≥ 16 years, treatment with a PHE-restricted diet from birth and/or
tetrahydrobiopterin (BH4) and IQ > 70.
A total of 116 eligible patients were contacted: 111 (97%) were
selected to participate in the study, considering gender, disease severity
and age criteria; reasons of exclusion were: refusal to participate
(n=4), and recent childbirth (n=1).
In our sample, 88 patients were affected by the classical form and 23
were affected by the mild form. A total of 92 patients were on PHE
restricted diet only; 19 patients over the last 4 years were found to be
BH4 responsive and therefore therapy was switched from dietary
treatment alone to BH4 treatment.
The study was carried out at five different Italian centers (listed
among authors' affiliations) distributed throughout the country
(North= 2; Centre= 2; South=1). Except for one center (Division of
Inherited metabolic diseases of Padova) all other patients were followed
by pediatricians or pediatric neurologists. These centers continue to
care for PKU patients even after they become adults. Transition pro-
gram is available in very few centers in Italy. Furthermore, these cen-
ters were chosen because their clinical team included a dedicated
psychologist.-.
The survey was developed based on a survey that was already used
for other chronic diseases, such as diabetes, and modified for PKU. It
has been already used in a single-center (Padua) pilot study.
Responders were asked to complete a two-section survey. The first part
of the survey addressed socio-demographic (family, school or work
environment, leisure time) and general clinical data, as well as disease-
related symptoms. Then, patients prescribed a low-PHE nutritional plan
only were asked to complete the second part of the survey, which in-
vestigated dietary habits and psychological factors influencing ad-
herence to diet more in depth. Standard operating methodology was
achieved before data collection by organizing a training session with all
involved healthcare professionals. At each center, all patients were
evaluated by the same medical doctor and psychologist. Specifically,
the former was responsible for survey explanation, written informed
consent and clinical examination, while the latter administered the
survey.
The study was performed in compliance with local regulatory re-
quirements and written informed consent was obtained from all sub-
jects or their legally authorized representatives.
2.1. Statistical analysis
Descriptive statistical analyses were carried out. Categorical vari-
ables were presented as counts and percentages, while continuous
variables were reported as mean and standard deviation (normal dis-
tribution) or median and inter-quartile range (IQR; non-normal dis-
tribution). Categorical variables were compared using Fisher's exact
test. All statistical analyses were performed using SAS® software (SAS
Institute Inc., Cary, NC, USA).
3. Results
A total of 111 patients answered the survey across the 5 metabolic
centers (Bari: 35, Padua: 34, Fano: 18, Rome: 16 and Piacenza: 8).
Regarding demographic features of the study population, these were
similar across recruiting centers: overall, 61 females (55%) and 50
males (45%); age range 19–30 years, mean 24 years old.
The first part of the survey was completed by all patients (n=111),
while results regarding dietary habits and psychological factors influ-
encing adherence to diet refer to patients not taking BH4 and following
a dietary prescription only (n=92).
Information on family, school or work environment, and leisure
time is reported in Table 1. Data appeared to be mainly in agreement
with those of the general Italian population [22]. Seven patients out of
111 (6.3%) claimed to study and work at the same time, while 17
Table 1
Information on family, school or work environment, and leisure time
(N=111).
Question N (%)
Category B driving license (YES) 83 (84.6)⁎
Who are you living with?
- Alone
- With my family
14 (12.6)
97 (87.4)
Are you married or do you have a partner? (YES) 54 (48.6)
(55.1)⁎
Please indicate your father's highest qualification in terms of
education:
- primary or junior high school leaving certificate (8 years of
education)
- high school leaving certificate (13 years of education)
- University Bachelor's degree or postgraduate diploma (≥16 years
of
education)
63 (56.8)
37 (33.3)
11 (9.9)
Please indicate your mother's highest qualification in terms of
education:
- primary or junior high school leaving certificate (8 years of
education)
- high school leaving certificate (13 years of education)
- University Bachelor's degree or postgraduate diploma (≥16 years
of
education)
74 (66.7)
30 (27.0)
7 (6.3)
Are you attending school? (YES)
- high school (13 years of education)
- University (≥16 years of education)
- Not specified
39 (35.1)
24
14
1
Are you currently working? (YES) 62 (55.9)
Does your work involve travelling? (YES) 12 (10.8)
Do you practice sports? (YES) 58 (52.3)
⁎ Calculated on those aged ≥18 years (n=98).
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patients (15.3%) were unemployed.
A total of 46 patients (40%) did not consider PKU a disease.
However, symptoms that could be ascribed to high plasma PHE levels
[8, 23] were reported often (at least twice a week) or even every day in
a significant proportion of patients (Fig. 1), particularly fatigue
(n=28; 25%), irritability (n=16; 14%), mood swings (n=14; 13%)
and difficulty in concentrating (n=13; 12%).
The number of attended examinations over the last 2 years was in
agreement with current guideline-based recommendations (57 patients
reported 2 examinations over the last 2 years) [4]. In addition, regular
monitoring of PHE plasma levels was reported by most patients
(n=94; 85%) (Table 2). However, an acceptable maximum PHE value
(< 600 μmol/L) over the last 6 months was reported by less than one
fourth of the patients (n=24; 22%) while about one third (n=34;
31%) did not specify it. In respect to this, there are no differences be-
tween patients on low PHE diet and patients taking BH4.
Regarding information on dietary habits, 74 patients (80%) re-
ported to generally have lunch or dinner out of home more than twice
per week and 39 patients (42%) reported to completely follow a low-
PHE nutritional plan. In respect to this, the habitual consumption (at
least once daily) of low-protein foods was reported by most patients
(n=80; 87%), while the mean daily use of amino acid (AA) mixtures
was rather low, with 17 patients (18.5%) reporting an optimal con-
sumption (4–5 times/day) [4]. Natural sources of protein were con-
sumed frequently (Fig. 2), particularly milk and other dairy products
(63 patients reported up to 7 times/week). The frequency of con-
sumption of other protein sources was usually 1–3 times/week.
Finally, we investigated factors influencing adherence to diet. We
asked which factors interfere the most with adherence to the con-
sumption of AA mixtures: the most relevant factors were the impact of
use on socializing (n=52; 56%), palatability (n=36; 39%), con-
sumption in a working environment (n=33; 36%), embarrassment in
consuming mixtures when out of home (n=32; 35%), travelling
(n=31; 34%) and low ease of use (n=30; 33%). (Fig. 3, Plot A).
Regarding factors that promote compliance with the nutritional plan,
plasma PHE periodical measurements (n=56; 61%), follow-up ex-
aminations at the metabolic center (n=46; 50%), being informed
about the disease (n=33; 36%) and support from family (n=33;
36%) – were indicated as the most important (Fig. 3, Plot B). For factors
influencing both the use of AA mixtures and compliance to PKU diet, no
significant differences between genders were observed with the ex-
ception of planning a pregnancy, which increased adherence to diet.
4. Discussion
Dietary treatment is the mainstay of PKU management and should
be continued for life [2]. Unfortunately, this proves to be inescapably
Fig. 1. Frequency (%) of main symptoms that could be ascribed to high plasma PHE levels in the overall study population.
Table 2
Clinical/metabolic features and dietary habits of the study population.
Question Overall
(n= 111)
On low-PHE
diet
(n= 92)
Please indicate the number of medical
examinations you have attended over the
last 2 years, median [IQR]
2 [2–3] 2 [2–3]
Do you monitor phenylalanine plasma levels
regularly? (YES)
94 (84.7) 81 (88)
What was your maximum value of phenylalanine
over the last 6months?
- ≤600 μmol/L
- 601-1000 μmol/L
- > 1000 μmol/L
- not reported
24 (21.6)
32 (28.8)
21 (18.9)
34 (30.7)
22 (23.9)
25 (27.2)
20 (21.7)
25 (27.2)
Do you take tetrahydrobiopterin (BH4)? (YES) 19 (17.2) 0 (0.0)
Do you adhere to a low-phenylalanine diet?
(YES)
92 (82.8) 92 (100)
Do you have lunch or dinner out? (YES) – 74 (80.4)
If you do, how often on average in a week? Mean
[SD]
– 2.6 [1.8]⁎
Please indicate the number of times you consume
an amino acid mixture daily Mean [SD] – 2.4 [1.3]
Do you have problems in taking your amino acid
mixtures with you while travelling? (YES) – 9 (9.8)
Please indicate whether you consume low
protein foods
- never
- sometimes (at least twice a week)
- habitually (at least once daily)
–
–
–
4 (4.3)
8 (8.6)
80 (87.1)
According to you, to what extent do you follow
your PKU diet? (Completely) – 39 (42.4)
Data are reported as count and percentage (between parentheses) unless
otherwise reported.
⁎ Calculated on those reporting to have lunch or dinner out (n= 74).
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arduous for adults, given the sheer scale of the required reduction in
dietary protein and the centrality of food to our cultural identities and
social relationships.
To our knowledge, this is the first Italian survey carried out on adult
patients diagnosed with PKU at birth, who have attended the same
metabolic clinic ever since. What is more, our survey focused on the
subjective perceptions of the patients instead of clinical data collected
by healthcare professionals, since the perceptions of the former do not
necessarily coincide with the perceptions of the latter. The survey has
thus provided unique information on how patients actually experience
PKU and related dietary treatment. The main finding was that com-
pliance with dietary recommendations among adult PKU patients was
poor, with less than half (42%) claiming full adherence, increased
consumption of natural protein sources and reduced daily use of amino-
acid supplements (< 4–5 times/day in 82% patients). Their claims were
supported by phenylalanine plasma concentration data: nearly half of
them reported a high plasma value over the last 6 months (> 600 μmol/
L, 48%) or were unable to specify it (31%). This is consistent with the
recent findings of the systematic review by Medford (2017) including
29 articles representing 1784 PKU patients of all ages, who found that
the main factor associated with worsening of metabolic control was age
[9], as well as a less recent retrospective chart review related to 125
PKU patients that showed that the proportion of adequately controlled
subjects diminished considerably after the age of 18 (39% vs 57% be-
tween the age of 6 and 17 years) [24] and general claims in reviews on
PKU in the literature [25]. Increasing age usually involves the transition
from a pediatric to an adult setting. Even at a center that managed the
transition successfully, not all adult PKU patients were adequately
controlled [26]. Also the failure to find differences between genders is
consistent with previous findings [9, 24].
The issue then becomes how important metabolic control is in adult
PKU patients. The European guidelines have recommended treatment
for life, with the exception of patients ≥12 years with untreated phe-
nylalanine levels< 600 μmol/l [2]. A recent nested, case-controlled
study using insurance claims databases [27], in which patients were
subdivided by age bracket, has shown that the prevalence of neu-
ropsychiatric conditions is higher in PKU patients than in the general
population, independently of age. In the overall PKU patient population
(n=3714) the prevalence of the following conditions was significantly
(p< 0.05) higher and at least 4 times the prevalence in the general
population: intellectual disability (Prevalence Ratio (PR) 7.9), autism
spectrum disorder (PR 6.1), Tourette / tic disorders (PR 5.4) and eating
disorders (PR 4.0). In the 20–39 year age bracket i.e. the one that re-
sembled our patient population the most (n=2242), the prevalence of
fatigue and attention disorders – issues that were reported by our in-
terviewees - were also significantly more common (PR 2.2 and 1.7,
respectively, both p<0.05). Our interviewees also reported mood
swings, which have been found to be associated with phenylalanine
concentrations (p= .039) [28].
Most of the factors impacting compliance with dietary treatment by
our interviewees had already been identified for inherited metabolic
diseases that required low-protein diet years ago. McDonald (2012)
[25] subdivided them into clusters: those related to AA supplements
(including two of the reasons listed i.e. lack of palatability and ease of
use), burden of diet (including the risk of social isolation that covers the
other three factors mentioned i.e. interference with socializing, diffi-
culty in working environment and embarrassment) and four additional
ones, namely the paradox of dietary treatment i.e. the lack of apparent
correlation between well-being and dietary adherence, patient respon-
sibility (including motivation, knowledge of treatment, development of
relevant skills required for self-care), family characteristics (socio-eco-
nomic status, cultural and religious factors, source of emotional sup-
port) and information.
The first of the additional four factors – the paradox – resulted to be
very important: nearly one half of the interviewees (40%) did not
consider PKU a disease and this lack of awareness could affect ad-
herence to dietary recommendations. Indeed, additional multivariate
analysis are necessary in order to highlight the possible correlation
between variables.
Also the second one - level of patient responsibility - applies here.
The American Academy of Pediatrics [29] recommends great care in
ensuring a well-timed and structured transition from child- to adult
oriented health care for any kind of chronic disease between the ages of
18 and 21 years. The Academy has developed an algorithm designed to
ensure coordination of patient, family and healthcare professional re-
sponsibilities and ensure that young adults are adequately empowered
so that they are in a position to take responsibility for self-care as an
adult. In a recent study on the adequacy of knowledge on the disease
Fig. 2. Prevalence of patients reporting the consumption of protein-containing foods.
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and dietary requirements in 173 PKU patients aged 10–19 and 110
parents of PKU children [30], 98% parents claimed to teach their
children to be self-reliant, but only 81% of the children confirmed that
this was true. What is worse, only 45% (n=74) of PKU patients knew
daily PHE intake recommendations and only 27% of patients (n=41)
knew the PHE content in a minimum of three out of four researched
food products. However, in this study lack of compliance was not just
due to ignorance, since 30% of patients reported feeling very ashamed
about their dietary restrictions and this appeared to induce them to
have a negative attitude towards dietary treatment.
The other two additional factors – family characteristics in terms of
socio-economic status and the level of education - have been found to
be closely correlated with adequate metabolic control in another, much
more common metabolic disorder, namely diabetes mellitus. A cross-
sectional, multicenter study, in 768 subjects with type 1 diabetes under
18 years of age [31] showed that metabolic control was very poor
(target HbAc1 values were achieved in only 28.1% of subjects) and was
significantly correlated to these two factors (p= .02 for both factors).
Studies in PKU on the importance of the socio-economic status of
the family have yielded inconsistent results [9]. The only common
feature related to poor metabolic control that has been consistently
found has been having divorced parents, likely because this indicates a
lower level of family support [32], one of the positive factors men-
tioned by our interviewees.
Although education has been mentioned as one of the factors in-
fluencing adherence to dietary treatment by PKU patients, our survey
showed the only one third of patients endorsed this item. A possible
explanation of this controversial point is the difference between theory
Fig. 3. Factors that were reported to interfere the most with adherence to the consumption of amino acid mixtures (numbers of patients reporting yes or no, Plot A)
and the nutritional plan for PKU (numbers of patients reporting yes or no) Plot B).
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and real life.However, although this factor is necessary, it is not suffi-
cient to guarantee adherence, since other psychological issues interfere
with motivation [9, 30]. This is where follow-up visits come in. Indeed,
they were listed among the important factors promoting compliance
and have proved to be the key to successful outcome in clinical practice
[26].
We acknowledge that our study is limited by its relatively small
sample size (n=111) reduced even further by the removal of results on
patients treated only with BH4 (N pts. on restricted diet =92). The
reason for the small sample size was not only the rarity of PKU, but also
the fact that the interview required a psychologist with experience with
PKU patients, who was a regular member of the clinical team. This
requirement was met by a network of 5 centers in Italy. The adult PKU
subgroup on treatment with BH4 was so small (n=19) that we could
not use the data to reach any conclusions. Results among this small
group of patients highlighted that metabolic control may be not optimal
in these patients also, therefore patients should be carefully monitored
and therapy evaluated for its appropriateness. Further studies are re-
quired to address the adequacy of treatment in PKU adult patients be-
longing to this subgroup.
In conclusion, we have ascertained that metabolic control and
compliance with dietary treatment in adult PKU patients are poor. The
main factors affecting compliance are lack of awareness of the con-
sequences, since some patients do not even consider a disease, psy-
chological difficulties in coping with dietary restrictions in society and
intrinsic negative features of AA supplements, whereas follow-up visits
and family support promote compliance.
These factors need to be addressed taking a series of specific mea-
sures: setting up educational initiatives with the objective of increasing
awareness about the condition and the need for lifelong dietary treat-
ment; ensuring regular follow-up, which is to include structured tran-
sition from adolescence to adulthood and interventions by a psychol-
ogist, as appropriate; making targeted interventions on dietary
treatment in the attempt to make it more acceptable, thus reducing its
burden in daily life.
Further studies should focus on patients aged between 10 and 14, in
order to identify factors (e.g psychological or dietary) associated with
compliance to low-PHE diet. Increased awareness on the importance of
adherence to diet and better long-term outcomes of the disease could be
achieved with more intense and tailored educational activities invol-
ving both patients and parents. Therefore, further studies are also re-
quired to examine interventions (e.g. structured transitional care pro-
cesses) to improve treatment adherence.
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